COMMUNIQUÉS West-GlobeNewswire

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care
10/06/2025
Novo Nordisk to present data from STEP UP trial on a higher dose of Wegovy ® (semaglutide 7.2 mg) for those in need of greater weight loss Data will expand semaglutide evidence in both a clinical and real-world setting [...]
Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Data at Clinical Trials at the Summit and MaculArt
10/06/2025
Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current injection-based treatments Company is exploring new [...]
Noom Expands Board of Directors with Appointment of Global Health Leader Dr. David Luu
10/06/2025
Dr. Luu’s experience as a visionary heart surgeon and longevity health-tech entrepreneur positions him to support Noom’s long-term strategic mission NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Noom , the leading digital [...]
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
10/06/2025
ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
Vivani Medical to Present at the 2025 BIO International Convention
10/06/2025
ALAMEDA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI ) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, [...]
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
10/06/2025
SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head [...]
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
10/06/2025
Ness-Ziona, Israel, June 10, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a [...]
GSAC Engineering Secures Multi-Year Recurring Revenue Contract
10/06/2025
GelStat’s Subsidiary Awarded Renewal for Security Monitoring Services and Expands Deployment of Proprietary iCAS Technology Across Three Secure Government-Operated Facilities in Florida MIAMI, June 10, 2025 (GLOBE [...]
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
10/06/2025
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will [...]
Rose Hill Life Sciences to Spotlight Leading Research Partners at Psychedelic Science 2025
10/06/2025
Dr. Gül Dölen, MD, PhD, to share groundbreaking research on how psychedelic compounds can reopen “critical periods” of brain plasticity. Rotem Petranker, PhD, to discuss the latest findings from controlled clinical [...]
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
10/06/2025
Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation [...]
Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program
10/06/2025
NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellence MALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. ( [...]
Iovance Biotherapeutics to Present at Upcoming Conference
10/06/2025
SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
10/06/2025
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today [...]
Roji Health Intelligence Achieves HITRUST e1 Certification Demonstrating Foundational Cybersecurity
10/06/2025
HITRUST e1 Certification validates Roji Health Intelligence is committed to foundational cybersecurity controls and information risk management CHICAGO, June 10, 2025 (GLOBE NEWSWIRE) -- Roji Health Intelligence LLC, a [...]
NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
10/06/2025
LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating attention-deficit [...]
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
10/06/2025
Study is Intended to Verify Previous Discovery Results Demonstrating Sensitivity of 95% and Specificity of 98% BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“ [...]
Progyny Joins Amazon’s Health Benefits Connector Program as First Women’s Health and Family Building Solution
10/06/2025
The collaboration will enable Amazon customers who are eligible for Progyny services to discover and enroll in fertility, family building, and menopause benefits. NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc [...]
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
10/06/2025
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock [...]

Pages